Up-regulated expression of type II very low density lipoprotein receptor correlates with cancer metastasis and has a potential link to β-catenin in different cancers

Table 5 Correlation between VLDLR II expression and clinical features in 51 Lung cancer patients

Parameters	Number	VLDLR II fold	P
Age at diagnosis
≥ 55 years	30	1.16 ± 0.25	0.781
< 55 years	21	1.11 ± 0.34
Gender
Male	35	1.12 ± 0.31	0.424
Female	16	1.19 ± 0.37
Body weight
≥ 60 kg	19	1.15 ± 0.22	0.823
< 60 kg	32	1.13 ± 0.32
TC
> 5.20 mmol/L	12	1.03 ± 0.20	0.096
≤ 5.20 mmol/L	39	1.16 ± 0.30
TG
> 1.70 mmol/L	9	1.01 ± 0.35	0.166
≤ 1.70 mmol/L	42	1.17 ± 0.27
Histological grade
Well to moderately differentiated	38	1.11 ± 0.29	0.133
Poorly differentiated	13	1.25 ± 0.27
Tumor size
≥ 5 cm	22	1.20 ± 0.30	0.254
< 5 cm	29	1.09 ± 0.28
Lymph node metastasis
Negative	15	1.01 ± 0.37	0.090
Positive	36	1.19 ± 0.23
Distant metastasis
Negative	40	1.06 ± 0.26	0.008*
Positive	11	1.36 ± 0.29
TNM stage
Stage I-II	25	1.06 ± 0.27	0.061
Stage III-IV	26	1.25 ± 0.29
Histological type
adenocarcinoma	18	1.22 ± 0.29	0.190
squamous cell carcinoma	24	1.11 ± 0.31
small cell carcinoma	6	1.03 ± 0.19
adeno-squamous carcinoma	3	1.09 ± 0.07

Folds (VLDLR II protein in tumor/in normal) in mean ± SD. VLDLR II measured by Western blot. TC, total cholesterol (normal range: ≤ 5.20 mmol/L); TG, triglycerides (normal range: ≤ 1.70 mmol/L). Statistical analyses were performed by Mann-Whitney test (for 2 groups) or Kruskal-Wallis test (for > 2 groups).
*P < 0.05 is considered significant.

ISSN: 1471-2407